November 18, 2024 \u00b7 6 min read<\/em><\/p>\n\n\n\n Personalized medicine is no longer a distant promise. Here are the five developments our research teams believe will define the landscape in the coming year.<\/p>\n\n\n\n Machine learning models are reducing early-stage discovery timelines from 4\u20135 years to approximately 18 months. Our internal data shows a 67% improvement in candidate identification accuracy since implementing AI tools in 2021.<\/p>\n\n\n\n Regulatory agencies in the EU, US, and Japan now require companion diagnostics for 23% of new oncology approvals, up from just 8% in 2018. This shift demands tighter integration between diagnostic and therapeutic development.<\/p>\n\n\n\n Remote patient monitoring and digital endpoints are enabling trials with participants in over 50 countries simultaneously. Our CARDIO-REMOTE study enrolled 2,847 patients across 31 nations without requiring a single in-person visit.<\/p>\n\n\n\n Production costs for viral vectors have dropped 42% since 2020. Three of our European manufacturing sites have completed upgrades to support commercial-scale gene therapy production by Q2 2025.<\/p>\n\n\n\n The FDA accepted real-world data as primary evidence in 14 approval decisions last year. We are investing \u20ac45 million in data infrastructure to capture outcomes from 1.2 million patients across our partner hospital networks.<\/p>\n\n\n\n1. AI-Driven Drug Discovery Accelerates<\/h2>\n\n\n\n
2. Biomarker Testing Becomes Standard<\/h2>\n\n\n\n
3. Decentralized Clinical Trials Expand<\/h2>\n\n\n\n
4. Gene Therapy Manufacturing Scales<\/h2>\n\n\n\n
5. Real-World Evidence Gains Regulatory Weight<\/h2>\n\n\n\n